Matulonis UA, Vergote I, Moore KN, Martin LP, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol 2025;200:96-104.
PMID: 40700855